187 related articles for article (PubMed ID: 33373589)
61. Early tumor shrinkage served as a prognostic factor for patients with stage III non-small cell lung cancer treated with concurrent chemoradiotherapy.
Wei M; Ye Q; Wang X; Wang M; Hu Y; Yang Y; Yang J; Cai J
Medicine (Baltimore); 2018 May; 97(19):e0632. PubMed ID: 29742701
[TBL] [Abstract][Full Text] [Related]
62. Influence of conformal radiotherapy technique on survival after chemoradiotherapy for patients with stage III non-small cell lung cancer in the National Cancer Data Base.
Sher DJ; Koshy M; Liptay MJ; Fidler MJ
Cancer; 2014 Jul; 120(13):2060-8. PubMed ID: 24692108
[TBL] [Abstract][Full Text] [Related]
63. Salvage surgery for locoregional recurrence or persistent tumor after high dose chemoradiotherapy for locally advanced non-small cell lung cancer.
Dickhoff C; Dahele M; Paul MA; van de Ven PM; de Langen AJ; Senan S; Smit EF; Hartemink KJ
Lung Cancer; 2016 Apr; 94():108-13. PubMed ID: 26973215
[TBL] [Abstract][Full Text] [Related]
64. Salvage Surgery Compared to Surgery After Induction Chemoradiation Therapy for Advanced Lung Cancer.
Kobayashi AK; Nakagawa K; Nakayama Y; Ohe Y; Yotsukura M; Uchida S; Asakura K; Yoshida Y; Watanabe SI
Ann Thorac Surg; 2022 Dec; 114(6):2087-2092. PubMed ID: 34843695
[TBL] [Abstract][Full Text] [Related]
65. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study.
Bradley JD; Paulus R; Komaki R; Masters G; Blumenschein G; Schild S; Bogart J; Hu C; Forster K; Magliocco A; Kavadi V; Garces YI; Narayan S; Iyengar P; Robinson C; Wynn RB; Koprowski C; Meng J; Beitler J; Gaur R; Curran W; Choy H
Lancet Oncol; 2015 Feb; 16(2):187-99. PubMed ID: 25601342
[TBL] [Abstract][Full Text] [Related]
66. Predictive factors for survival in stage IIIA N2 NSCLC patients treated with neoadjuvant CCRT followed by surgery.
Lim HJ; Lee HY; Lee KS; Han J; Kwon OJ; Park K; Ahn YC; Kim BT; Shim YM
Cancer Chemother Pharmacol; 2015 Jan; 75(1):77-85. PubMed ID: 25374409
[TBL] [Abstract][Full Text] [Related]
67. Introducing FDG PET/CT-guided chemoradiotherapy for stage III NSCLC in low- and middle-income countries: preliminary results from the IAEA PERTAIN trial.
Konert T; Vogel WV; Paez D; Polo A; Fidarova E; Carvalho H; Duarte PS; Zuliani AC; Santos AO; Altuhhova D; Karusoo L; Kapoor R; Sood A; Khader J; Al-Ibraheem A; Numair Y; Abubaker S; Soydal C; Kütük T; Le TA; Canh NX; Bieu BQ; Ha LN; Belderbos JSA; MacManus MP; Thorwarth D; Hanna GG
Eur J Nucl Med Mol Imaging; 2019 Oct; 46(11):2235-2243. PubMed ID: 31367906
[TBL] [Abstract][Full Text] [Related]
68. Clinical Impact of Frequent Surveillance Imaging in the First Year Following Chemoradiation for Locally Advanced Non-small-cell Lung Cancer.
Ho QA; Harandi NK; Daly ME
Clin Lung Cancer; 2017 Jul; 18(4):410-414. PubMed ID: 28007410
[TBL] [Abstract][Full Text] [Related]
69. Efficacy and toxicity of chemoradiotherapy with carboplatin and irinotecan followed by consolidation docetaxel for unresectable stage III non-small cell lung cancer.
Bastos BR; Hatoum GF; Walker GR; Tolba K; Takita C; Gomez J; Santos ES; Lopes G; Raez LE
J Thorac Oncol; 2010 Apr; 5(4):533-9. PubMed ID: 20357618
[TBL] [Abstract][Full Text] [Related]
70. Impact of chemoradiotherapy on the immune-related tumour microenvironment and efficacy of anti-PD-(L)1 therapy for recurrences after chemoradiotherapy in patients with unresectable locally advanced non-small cell lung cancer.
Shirasawa M; Yoshida T; Matsumoto Y; Shinno Y; Okuma Y; Goto Y; Horinouchi H; Yamamoto N; Watanabe SI; Ohe Y; Motoi N
Eur J Cancer; 2020 Nov; 140():28-36. PubMed ID: 33039811
[TBL] [Abstract][Full Text] [Related]
71. Patterns of locoregional failure in stage III non-small cell lung cancer treated with definitive chemoradiation therapy.
Garg S; Gielda BT; Kiel K; Turian JV; Fidler MJ; Batus M; Bonomi P; Sher DJ
Pract Radiat Oncol; 2014; 4(5):342-348. PubMed ID: 25194104
[TBL] [Abstract][Full Text] [Related]
72. Epidermal growth factor receptor mutation is associated with longer local control after definitive chemoradiotherapy in patients with stage III nonsquamous non-small-cell lung cancer.
Yagishita S; Horinouchi H; Katsui Taniyama T; Nakamichi S; Kitazono S; Mizugaki H; Kanda S; Fujiwara Y; Nokihara H; Yamamoto N; Sumi M; Shiraishi K; Kohno T; Furuta K; Tsuta K; Tamura T
Int J Radiat Oncol Biol Phys; 2015 Jan; 91(1):140-8. PubMed ID: 25442336
[TBL] [Abstract][Full Text] [Related]
73. Impact of prior chemoradiotherapy-related variables on outcomes with durvalumab in unresectable Stage III NSCLC (PACIFIC).
Faivre-Finn C; Spigel DR; Senan S; Langer C; Perez BA; Özgüroğlu M; Daniel D; Villegas A; Vicente D; Hui R; Murakami S; Paz-Ares L; Broadhurst H; Wadsworth C; Dennis PA; Antonia SJ
Lung Cancer; 2021 Jan; 151():30-38. PubMed ID: 33285469
[TBL] [Abstract][Full Text] [Related]
74. Reactivation of TB during administration of durvalumab after chemoradiotherapy for non-small-cell lung cancer: a case report.
Kato Y; Watanabe Y; Yamane Y; Mizutani H; Kurimoto F; Sakai H
Immunotherapy; 2020 Apr; 12(6):373-378. PubMed ID: 32314636
[No Abstract] [Full Text] [Related]
75. Outcomes of neoadjuvant concurrent chemoradiotherapy followed by surgery for non-small-cell lung cancer with N2 disease.
Kim HK; Cho JH; Choi YS; Zo JI; Shim YM; Park K; Ahn MJ; Ahn YC; Kim K; Kim J
Lung Cancer; 2016 Jun; 96():56-62. PubMed ID: 27133751
[TBL] [Abstract][Full Text] [Related]
76. Salvage Surgery for Bronchopleural Fistula Due to Durvalumab and Chemoradiation.
Tada M; Uehara H; Ohyu T; Watanabe A
Ann Thorac Surg; 2022 Sep; 114(3):e185-e187. PubMed ID: 34973185
[TBL] [Abstract][Full Text] [Related]
77. Salvage surgery for local failures after stereotactic ablative radiotherapy for early stage non-small cell lung cancer.
Verstegen NE; Maat AP; Lagerwaard FJ; Paul MA; Versteegh MI; Joosten JJ; Lastdrager W; Smit EF; Slotman BJ; Nuyttens JJ; Senan S
Radiat Oncol; 2016 Oct; 11(1):131. PubMed ID: 27716240
[TBL] [Abstract][Full Text] [Related]
78. Locally Advanced, Unresectable Non-Small Cell Lung Cancer.
Puri S; Saltos A; Perez B; Le X; Gray JE
Curr Oncol Rep; 2020 Mar; 22(4):31. PubMed ID: 32140986
[TBL] [Abstract][Full Text] [Related]
79. Is post-treatment standardized uptake value a prognostic factor in unresectable non-small cell lung carcinoma?
Yılmaz U; Yasar Z; Korkmaz E; Yalcın B; Koparal H; Ozbilek E
Med Glas (Zenica); 2017 Aug; 14(2):204-210. PubMed ID: 28698535
[TBL] [Abstract][Full Text] [Related]
80. Impact of EGFR Mutation and ALK Translocation on Recurrence Pattern After Definitive Chemoradiotherapy for Inoperable Stage III Non-squamous Non-small-cell Lung Cancer.
Nakamura M; Kageyama SI; Niho S; Okumura M; Hojo H; Motegi A; Nakamura N; Zenda S; Yoh K; Goto K; Akimoto T
Clin Lung Cancer; 2019 May; 20(3):e256-e264. PubMed ID: 30926356
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
